Plain-English fact sheet
Humanin
Also known as HN, MT-RNR2 peptide, S14G-humanin (experimental analog)
Humanin is an intriguing mitochondrial signaling peptide, but claims about cognition, Alzheimer's disease, longevity, or muscle protection remain preclinical or observational.
Quick answer
Humanin is a naturally occurring mitochondrial-derived peptide studied in cell survival, neurodegeneration, metabolism, and aging. No humanin drug product is FDA approved, and there is no convincing clinical trial evidence that taking a humanin product improves cognition or extends healthy life.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is Humanin?
Humanin is a short peptide encoded within the mitochondrial MT-RNR2 region and involved in stress-response and cell-survival signaling.
Researchers also study more potent synthetic analogs such as S14G-humanin; results from an analog, a cell experiment, or a blood-level association do not prove a treatment effect from native humanin.
Why are people interested in it?
Cell and animal models report neuroprotective, metabolic, retinal, cardiovascular, and anti-apoptotic signals.
Human genetics and biomarker studies link Humanin biology with cognitive aging or disease, but those associations are not trials of a humanin medicine.
Current regulatory status
No humanin or humanin-analog product is FDA approved. Human therapeutic development has not produced a mature clinical program establishing benefit for cognition, neurodegeneration, metabolism, or aging.
What is it approved for?
No FDA-approved use. This matters because clinical-trial participation and products marketed online are not the same as an approved medicine.
What is it being studied for?
Investigational areas
- Neurodegenerative-disease mechanisms
- Mitochondrial and metabolic stress
- Healthy-aging and muscle-protection research
Evidence snapshot
The treatment literature is dominated by cell and animal studies. Human studies are primarily observational, genetic, or biomarker research and cannot show that administering humanin improves outcomes.
Potential benefits being researched
- Laboratory and animal studies report protection from selected toxic or metabolic stresses.
- A human genetic association study linked a variant associated with lower circulating humanin to cognitive aging, but did not test humanin treatment.
Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.
Known or possible risks
- A reliable human treatment safety profile has not been established.
- Analog identity, exposure, immune reactions, off-target signaling, and long-term effects remain poorly defined.
- Products sold outside an approved application add quality, purity, sterility, strength, and labeling uncertainty.
What we still do not know
- Whether humanin or an analog can improve any clinical outcome in people
- Which molecule, formulation, and target population would be appropriate for trials
- Short- and long-term safety
- Whether observational links with aging or cognition are causal
Plain-English takeaway
Humanin connects mitochondria, cell survival, and brain-aging research in fascinating ways. Today, however, it is a preclinical research subject—not a proven cognitive, muscle, or longevity therapy.
Research and reference links
Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.
- 1Humanin and cognitive aging study
Cell, animal, and human genetic-association findings; not a human treatment trial.
- 2Humanin lifespan and healthspan research
Multi-species preclinical and observational study that does not establish a human longevity treatment.
- 3Humanin retinal-cell protection study
Laboratory study in retinal pigment epithelial cells supporting preclinical mechanisms.
- 4Humanin and MOTS-c in cultured human muscle cells
2026 laboratory study in human muscle cells, not a clinical trial in people.